Developing a tool for noninvasive monitoring of renal allografts

Expert Review of Proteomics

Volumn 3, Issue 5, 2006, Pages 497-509

  Schaub, Stefan ^a   Wilkins, John A ^b   Rush, David ^b   Nickerson, Peter ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Allograft rejection; Noninvasive monitoring; Proteomics; Renal transplantation

Indexed keywords

ACTIN; ALPHA 1 MICROGLOBULIN; AZATHIOPRINE; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CALCINEURIN INHIBITOR; CD45 ANTIGEN; CREATININE; CYCLOSPORIN; CYSTATIN C; CYTOKINE; HLA ANTIBODY; HLA ANTIGEN; INTERLEUKIN 18; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

BLOOD ANALYSIS; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSPOT ASSAY; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; IMMUNITY; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEPHROTOXICITY; NON INVASIVE PROCEDURE; PATHOPHYSIOLOGY; PATIENT CARE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEOMICS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; T LYMPHOCYTE; TISSUE INJURY; URINALYSIS;

ANIMALS; BIOLOGICAL MARKERS; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PROTEOMICS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33750626759     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.3.5.497     Document Type: Review

References (98)

1. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am. J. Transplant. 3, 1488-1500 (2003).
2. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am. J. Transplant. 3, 708-714 (2003).
3. Gloor JM, Cohen AJ, Lager DJ et al. Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation 73, 1965-1968 (2002).
4. Hirsch HH, Brennan DC, Drachenberg CB et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 79, 1277-1286 (2005).
5. Nankivell BJ, Borrows RJ, Fung CL et al. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 78, 242-249 (2004).
6. Lindholm A, Albrechtsen D, Frodin L et al. Ischemic heart disease - major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 60, 451-457 (1995).
7. Holdaas H, Fellstrom B, Cole E et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am. J. Transplant. 5, 2929-2936 (2005).
8. Heeger PS, Hricik D. Immune monitoring in kidney transplant recipients revisited. J. Am. Soc. Nephrol. 13, 288-290 (2002).
9. Hricik DE, Heeger PS. Minimization of immunosuppression in kidney transplantation. The need for immune monitoring. Transplantation 72, S32-S35 (2001).
10. Kirk AD, Mannon RB, Swanson SJ, Hale DA. Strategies for minimizing immunosuppression in kidney transplantation. Transpl. Int. 18, 2-14 (2005). Excellent review summarizing current efforts and strategies to minimize immunosuppression.
11. Hoitsma AJ, Wetzels JF, van Lier HJ, Berden JH, Koene RA. Cyclosporin treatment with conversion after three months versus conventional immunosuppression in renal allograft recipients. Lancet 1, 584-586 (1987).
12. Morris PJ, Chapman JR, Allen RD et al. Cyclosporin conversion versus conventional immunosuppression: long-term follow-up and histological evaluation. Lancet 1, 586-591 (1987).
13. Hazzan M, Labalette M, Copin MC et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J. Am. Soc. Nephrol. 16, 2509-2516 (2005).
14. Abramowicz D, Del Carmen RM, Vitko S et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J. Am. Soc. Nephrol. 16, 2234-2240 (2005).
15. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J. Am. Soc. Nephrol. 13, 1365-1373 (2002).
16. Schnuelle P, van der Heide JH, Tegzess A et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J. Am. Soc. Nephrol. 13, 536-543 (2002).
17. Borrows R, Chan K, Loucaidou M et al. Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. Transplantation 81, 125-128 (2006).
18. Ter Meulen CG, van Riemsdijk I, Hene RJ et al. Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor α therapy: a prospective, randomized, multicenter study. Am. J. Transplant. 4, 803-810 (2004).
19. Woodle ES, Alloway RR, Buell JF et al. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am. J. Transplant. 5, 2740-2744 (2005).
20. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 349, 2326-2333 (2003).
21. Rush D, Nickerson P, Gough J et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J. Am. Soc. Nephrol. 9, 2129-2134 (1998).
22. Rush DN, Henry SF, Jeffery JR, Schroeder TJ, Gough J. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation 57, 208-211 (1994).
23. Moreso F, Ibernon M, Goma M et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am. J. Transplant. 6, 747-752 (2006).
24. Grimm PC, Nickerson P, Gough J et al. Computerized image analysis of sirius red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J. Am. Soc. Nephrol. 14, 1662-1668 (2003).
25. Nickerson P, Jeffery J, Gough J et al. Effect of increasing baseline immunosuppression on the prevalence of clinical and subclinical rejection: a pilot study. J. Am. Soc. Nephrol. 10, 1801-1805 (1999).
26. Nicholson ML, Wheatley TJ, Doughman TM et al. A prospective randomized trial of three different sizes of core-cutting needle for renal transplant biopsy. Kidney Int. 58, 390-395 (2000).
27. Hernandez-Fuentes MP, Warrens AN, Lechler RI. Immunologic monitoring. Immunol. Rev. 196, 247-264 (2003). Excellent review of antigen-specific cell-based assays for alloimmune monitoring.
28. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 75, 43-49 (2003). Describes the technology used to detect human leukocyte antigen (HLA)-antibodies and to determine their specificity.
29. Hourmant M, Cesbron-Gautier A, Terasaki PI et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J. Am. Soc. Nephrol. 16, 2804-2812 (2005).
30. Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 80, 1194-1197 (2005).
31. Augustine JJ, Siu DS, Clemente MJ et al. Pre-transplant IFN-γ ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am. J. Transplant. 5, 1971-1975 (2005).
32. Hricik DE, Rodriguez V, Riley J et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am. J. Transplant. 3, 878-884 (2003). Demonstrates that alloreactive T-cells measured by enzyme-linked immunosorbent spot (ELISPOT) are associated with inferior allograft function.
33. Poggio ED, Clemente M, Riley J et al. Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J. Am. Soc. Nephrol. 15, 1952-1960 (2004).
34. Nickel P, Presber F, Bold G et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-γ-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 78, 1640-1646 (2004).
35. Martin L, Guignier F, Bocrie O et al. Detection of anti-HLA antibodies with flow cytometry in needle core biopsies of renal transplants recipients with chronic allograft nephropathy. Transplantation 79, 1459-1461 (2005).
36. Grimm PC, McKenna R, Nickerson P et al. Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J. Am. Soc. Nephrol. 10, 1582-1589 (1999).
37. Karpinski M, Rush D, Jeffery J et al. Heightened peripheral blood lymphocyte cd69 expression is neither sensitive nor specific as a noninvasive diagnostic test for renal allograft rejection. J. Am. Soc. Nephrol. 14, 226-233 (2003).
38. Roberti I, Reisman L. Serial evaluation of cell surface markers for immune activation after acute renal allograft rejection by urine flow cytometry - correlation with clinical outcome. Transplantation 71, 1317-1320 (2001).
39. Ding R, Li B, Muthukumar T et al. CD103 mRNA levels in urinary cells predict acute rejection of renal allografts. Transplantation 75, 1307-1312 (2003).
40. Li B, Hartono C, Ding R et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N. Engl. J. Med. 344, 947-954 (2001).
41. Muthukumar T, Dadhania D, Ding R et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N. Engl. J. Med. 353, 2342-2351 (2005).
42. Muthukumar T, Ding R, Dadhania D et al. Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. Transplantation 75, 1565-1570 (2003).
43. Sadeghi M, Daniel V, Wiesel M, Hergesell O, Opelz G. High urine sIL-6R as a predictor of late graft failure in renal transplant recipients. Transplantation 76, 1190-1194 (2003).
44. Brown FG, Nikolic-Paterson DJ, Chadban SJ et al. Urine macrophage migration inhibitory factor concentrations as a diagnostic tool in human renal allograft rejection. Transplantation 71, 1777-1783 (2001).
45. Hauser IA, Spiegler S, Kiss E et al. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-γ (MIG). J. Am. Soc. Nephrol. 16, 1849-1858 (2005).
46. Hu H, Aizenstein BD, Puchalski A et al. Elevation of CXCR3-binding chemokines in urine indicates acute renal-allograft dysfunction. Am. J. Transplant. 4, 432-437 (2004).
47. Matz M, Beyer J, Wunsch D et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int. 69(9), 1683-1690 (2006).
48. Nankivell BJ, Borrows RJ, Fung CL et al. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 78, 434-441 (2004).
49. Robertson H, Ali S, McDonnell BJ, Burt AD, Kirby JA. Chronic renal allograft dysfunction: the role of T cell-mediated tubular epithelial to mesenchymal cell transition. J. Am. Soc. Nephrol. 15, 390-397 (2004).
50. Camara NO, Silva MS, Nishida S, Pereira AB, Pacheco-Silva A. Proximal tubular dysfunction is associated with chronic allograft nephropathy and decreased long-term renal-graft survival. Transplantation 78, 269-275 (2004).
51. Teppo AM, Honkanen E, Finne P, Tornroth T, Gronhagen-Riska C. Increased urinary excretion of à1-microglobulin at 6 months after transplantation is associated with urinary excretion of transforming growth factor-á1 and indicates poor long-term renal outcome. Transplantation 78, 719-724 (2004).
52. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am. J. Transplant. 4, 378-383 (2004).
53. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am. J. Transplant. 4, 1289-1295 (2004).
54. Herget-Rosenthal S, Poppen D, Husing J et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin. Chem. 50, 552-558 (2004).
55. Mishra J, Dent C, Tarabishi R et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365, 1231-1238 (2005).
56. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 62, 237-244 (2002).
57. + exchanger isoform 3 (NHE3) protein as new marker of tubule injury in critically ill patients with ARF. Am. J. Kidney Dis. 42, 497-506 (2003).
58. Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am. J. Kidney Dis. 43, 405-414 (2004).
59. Supavekin S, Zhang W, Kucherlapati R et al. Differential gene expression following early renal ischemia/reperfusion. Kidney Int. 63, 1714-1724 (2003).
60. Mishra J, Ma Q, Prada A et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 14, 2534-2543 (2003).
61. Sarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N. Engl. J. Med. 349, 125-138 (2003).
62. Scherer A, Krause A, Walker JR et al. Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. Transplantation 75, 1323-1330 (2003).
63. Famulski KS, Einecke G, Reeve J et al. Changes in the transcriptome in allograft rejection: IFN-gamma-induced transcripts in mouse kidney allografts. Am. J. Transplant. 6, 1342-1354 (2006).
64. Deng MC, Eisen HJ, Mehra MR et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am. J. Transplant. 6, 150-160 (2006).
65. Chua MS, Mansfield E, Sarwal M. Applications of microarrays to renal transplantation: progress and possibilities. Front Biosci. 8, S913-S923 (2003).
66. Mansfield ES, Sarwal MM. Arraying the orchestration of allograft pathology. Am. J. Transplant. 4, 853-862 (2004).
67. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet 365, 488-492 (2005).
68. Halloran PF, Reeve J, Kaplan B. Lies, damn lies, and statistics: the perils of the P value. Am. J. Transplant. 6, 10-11 (2006).
69. Thongboonkerd V. Proteomics in nephrology: current status and future directions. Am. J. Nephrol. 24, 360-378 (2004).
70. Tirumalai RS, Chan KC, Prieto DA et al. Characterization of the low molecular weight human serum proteome. Mol. Cell. Proteomics 2, 1096-1103 (2003).
71. Donaldson MD, Chambers RE, Woolridge MW, Whicher JT. Stability of αβ 1-microglobulin, β 2-microglobulin and retinol binding protein in urine. Clin. Chim. Acta 179, 73-77 (1989).
72. Baggerman G, Vierstraete E, De Loof A, Schoofs L. Gel-based versus gel-free proteomics: a review. Comb. Chem High Throughput Screen. 8, 669-677 (2005).
73. Steel LF, Haab BB, Hanash SM. Methods of comparative proteomic profiling for disease diagnostics. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.815, 275-284 (2005).
74. Schaub S, Wilkins J, Weiler T et al. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int. 65, 323-332 (2004).
75. O'Riordan E, Orlova TN, Mei JJ et al. Bioinformatic analysis of the urine proteome of acute allograft rejection. J. Am. Soc. Nephrol. 15, 3240-3248 (2004).
76. Clarke W, Silverman BC, Zhang Z et al. Characterization of renal allograft rejection by urinary proteomic analysis. Ann. Surg. 237, 660-665 (2003).
77. Wittke S, Haubitz M, Walden M et al. Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am. J. Transplant. 5, 2479-2488 (2005).
78. Schaub S, Rush D, Wilkins J et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 15, 219-227 (2004).
79. 2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am. J. Transplant. 5, 729-738 (2005). Demonstrates the use of proteomic technology for detailed analysis of a potential biomarker for tubular injury.
80. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J. Am. Soc. Nephrol. 15, 1677-1689 (2004). Excellent review of basic concepts and potential pitfalls of protein biomarker discovery and development.
81. Poggio ED, Clemente M, Hricik DE, Heeger PS. Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates. J. Am. Soc. Nephrol. 17, 564-572 (2006).
82. Andree H, Nickel P, Nasiadko C et al. Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J. Am. Soc. Nephrol. 17, 573-580 (2006).
83. Wahrmann M, Exner M, Haidbauer B et al. C4d FlowPRA screening - a specific assay for selective detection of complement-activating anti-HLA alloantibodies. Hum. Immunol. 66, 526-534 (2005).
84. Yussim A, Israeli M, Mor E, Krest D, Klein T. Evaluation of Immunknow-immune cell function assay as a new parameter of net state of immunosuppression in monitoring renal transplant recipients. Presented at: Am. Soc. Histocompatability Immunogenetics 31st Annual Meeting. WA, USA 17-20 October (2005).
85. Kowalski RJ, Post DR, Mannon RB, Sebastian A et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82, 663-668 (2006).
86. Burkhardt K, Radespiel-Troger M, Rupprecht HD et al. An increase in myeloid-related protein serum levels precedes acute renal allograft rejection. J. Am. Soc. Nephrol. 12, 1947-1957 (2001).
87. Matinlauri IH, Kyllonen LE, Salmela KT et al. Serum sCD30 in monitoring of alloresponse in well HLA-matched cadaveric kidney transplantations. Transplantation 80, 1809-1812 (2005).
88. Pelzl S, Opelz G, Daniel V, Wiesel M, Susal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 75, 421-423 (2003).
89. Susal C, Pelzl S, Dohler B, Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J. Am. Soc. Nephrol. 13, 1650-1656 (2002).
90. Rajakariar R, Jivanji N, Varagunam M et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection. Am. J. Transplant. 5, 1922-1925 (2005).
91. Simon T, Opelz G, Wiesel M, Ott RC, Susal C. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am. J. Transplant. 3, 1121-1127 (2003).
92. Mas VR, Maluf DG, Archer KJ et al. Study of mRNA growth factors in urinary cells of kidney transplant recipients as predictors of chronic allograft nephropathy. Transplantation 80, 1686-1691 (2005).
93. Teppo AM, Honkanen E, Ahonen J, Gronhagen-Riska C. Changes of urinary α1-microglobulin in the assessment of prognosis in renal transplant recipients. Transplantation 70, 1154-1159 (2000).
94. Kwon O, Molitoris BA, Pescovitz M, Kelly KJ. Urinary actin, interleukin-6, and interleukin-8 may predict sustained ARF after ischemic injury in renal allografts. Am. J. Kidney Dis. 41, 1074-1087 (2003).
95. Prischl F, Gremmel F, Schwabe M et al. β-2-microglobulin for differentiation between ciclosporin A nephrotoxicity and graft rejection in renal transplant recipients. Nephron 51, 330-337 (1989).
96. Roxe DM, Siddiqui F, Santhanam S, del Greco F, Wolf J. Rationale and application of β-2-microglobulin measurements to detect acute transplant rejection. Nephron 27, 260-264 (1981).
97. Parikh CR, Jani A, Mishra J et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am. J. Transplant. 6, 1639-1645 (2006).
98. Westhuyzen J, Endre ZH, Reece G et al. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol. Dial. Transplant. 18, 543-551 (2003).